Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.48 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771607 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1S1PR5SLC6A1CYP1A2 | |
| SCHEMBL740141 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1S1PR5SLC6A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL19638092 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1S1PR5LMNA | |
| Hydrochloric Acid SCHEMBL613075 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1S1PR5LMNA | |
| SCHEMBL13740434 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| SCHEMBL934458 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| SCHEMBL13739335 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| Hydrochloric Acid SCHEMBL28596153 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| SCHEMBL3842738 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1SLC6A1CYP1A2CYP2D6 | |
| Aniline SCHEMBL27948912 | 0.85 | ALDH1A1 (0.55) | ALDH1A1SLC6A1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20210284621-A1 | CANNABINOIDS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| WO-2021121282-A1 | PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS WITH IMMUNOMODULATORY FUNCTION | 上海轶诺药业有限公司 | 2021-06-24 | — | — | WO | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-9777020-B2 | Furo-3-carboxamide derivatives and methods of use | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2011131975-A1 | MICROSOMAL PROSTAGLANDIN E SYNTASE-1 INHIBITORS | Convergence Pharmaceuticals Limited (GB) | 2011-10-27 | — | — | WO | disclosed |
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-7390825-B1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | OXA1L, OTC, ODC1 | SMN1; SMN2 2201/4885ALDH1A1 2186/4885S1PR5 4300/4885 |
| US-20210284621-A1 | CANNABINOIDS AND USES THEREOF | CNR2, CNR1, FAAH | SMN1; SMN2 2897/4885ALDH1A1 2486/4885S1PR5 24/4885 |
| US-20110086853-A1 | Therapeutic Compounds | OPRL1, F12, F3 | SMN1; SMN2 41/4885ALDH1A1 364/4885S1PR5 450/4885 |
| US-20100022590-A1 | Novel compounds | HSD11B1, CYP11B1, HSD11B2 | SMN1; SMN2 3935/4885ALDH1A1 164/4885S1PR5 2936/4885 |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | NTRK2, MUSK, NTRK3 | SMN1; SMN2 833/4885ALDH1A1 2033/4885S1PR5 462/4885 |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | OXA1L, OGFOD1, CYP51A1 | SMN1; SMN2 1713/4885ALDH1A1 1117/4885S1PR5 3381/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | SMN1; SMN2 4445/4885ALDH1A1 1587/4885S1PR5 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.